Lung Cancer Therapy: The Role of Personalized Medicine
Cancers · 21.02.2025 · 17 (5) · 725
DOI: 10.3390/cancers17050725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.02.2025. Verfasst von Raquel Ramos und 9 weiteren Autor:innen. Beteiligte Einrichtung: PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo Europeu de Desenvolvimento Regional (FEDER), Fundação para a Ciência e a Tecnologia (FCT), CHAIR in Onco-Innovationfrom Faculty of Medicine, University of Porto (FMUP).
Abstract (Originalsprache)
Lung cancer is the deadliest cancer worldwide, exhibiting the highest incidence rate among all cancer types. Poor outcomes often characterize this cancer as it is commonly diagnosed in advanced stages due to its unspecific symptoms. After diagnosis, the therapeutic choice is a crucial stage that profoundly affects patients’ survival. Treatment choices for lung cancer must be made carefully, acknowledging the histological type and genetic characteristics of the tumor. Non-small cell lung cancer, the most common and complex type, has a high mutational burden, making next-generation sequencing (NGS) essential for identifying specific mutations and guiding treatment. With several approved targeted therapies already available, this approach highlights the critical role of personalized medicine in lung cancer care. Despite the current therapeutic pipeline, research trying to develop new tailored drugs considering individual patient characteristics has evolved over the years. This article aims to outline the current therapeutic approach for each type of lung cancer and present the latest insights into emerging therapies, highlighting the role of personalized medicine in enhancing treatment outcomes and improving patients’ quality of life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
- RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
- Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Leça do Balio, Portugal.
- Pathology Laboratory, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal.
- Anatomic Pathology Service, Pathology Department, Centro Hospitalar Universitário de Santo António (CHUdSA), Largo Professor Abel Salazar, 4099-001 Porto, Portugal.
- Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, Rua da Universidade, 4710-057 Braga, Portugal.
ORCID-Profile: Raquel Ramos, Carlos Sousa, Nuno Vale
Förderung
- Fundo Europeu de Desenvolvimento Regional (FEDER)
- Fundação para a Ciência e a Tecnologia (FCT)
- CHAIR in Onco-Innovationfrom Faculty of Medicine, University of Porto (FMUP)
Zitieren
APA
Ramos, R., Moura, C. S., Costa, M., Lamas, N. J., Correia, R., Garcez, D., Pereira, J. M., Lindahl, T., Sousa, C., & Vale, N. (2025). Lung Cancer Therapy: The Role of Personalized Medicine. Cancers, 17(5), 725. https://doi.org/10.3390/cancers17050725
Vancouver
Ramos R, Moura CS, Costa M, Lamas NJ, Correia R, Garcez D, et al. Lung Cancer Therapy: The Role of Personalized Medicine. Cancers. 2025;17(5):725. doi:10.3390/cancers17050725
BibTeX
@article{Ramos2025,
author = {Ramos, Raquel and Moura, Conceição Souto and Costa, Mariana and Lamas, Nuno Jorge and Correia, Renato and Garcez, Diogo and Pereira, José Miguel and Lindahl, Thomas and Sousa, Carlos and Vale, Nuno},
title = {Lung Cancer Therapy: The Role of Personalized Medicine},
journal = {Cancers},
year = {2025},
volume = {17},
number = {5},
pages = {725},
doi = {10.3390/cancers17050725}
}
EUVIMED